Meticulous Research®– leading global market research company published a research report titled “Influenza Diagnostics Market, by Test Type {[Traditional (RIDT, Direct Fluorescent Antibody, Viral Culture, Serology), Molecular [RT-PCR, INAAT (NASBA, LAMP)]}, End User (Hospitals, Laboratories, Academics, Research Institutes) - Forecast to 2027”.
According to this latest publication from Meticulous Research®, the global influenza diagnostics market is expected to grow at a CAGR of 7.9% from 2020 to reach $1.17 billion by 2027. The growth of Influenza diagnostics market is mainly driven by the factors such as increasing prevalence of influenza, growing awareness for early detection using specific diagnostic tests, development of CLIA-waived POC molecular influenza tests, and shifting focus from centralized laboratories to decentralized point-of-care testing. Moreover, advances in genomics and proteomics; and emerging markets such as India, Brazil, China, and others creates significant growth opportunities in this market.
The global Influenza diagnostics market study published by Meticulous Research® presents historical market data in terms of value (2018 and 2019), estimated current data (2020), and forecasts for 2027 by test type (traditional diagnostic tests, molecular diagnostic tests), and end user (hospital & clinical laboratories, diagnostic reference laboratories, academic/research institutes, and others). The study also evaluates industry competitors and analyzes the market at regional and country level.
Check complete table of contents with list of table and figures: https://www.meticulousresearch.com/product/influenza-diagnostics-market-5099/?utm_source=freepr&utm_medium=social&utm_campaign=Product&utm_content=22-11-22
Based on the test type, the traditional diagnostic tests segment is estimated to account for the largest share of the overall Influenza diagnostics market in 2020. However, the molecular diagnostic tests segment is expected to grow at the fastest growth rate during the forecast period, due to their ability to identify mutated and non-mutated viral strains in real-time and are more specific, sensitive, and reproducible methods of diagnostic testing. Less requirement of the template material for the overall test is also supporting the growing use of molecular test formats. Increasing utilization of RT-PCR in proteomics & genomics and growing need for rapid diagnosis of viral & infectious diseases are some of the other factors expected to drive the growth of this segment.
Based on end user, the hospitals & clinical laboratories segment is estimated to command the largest share of the overall influenza diagnostics market in 2020. The diagnostic reference laboratories segment is projected to register the fastest CAGR during the forecast period, mainly due to their nature of supporting the diagnosis required in patient care as well as medical research. Moreover, owing to curtailed reimbursements for laboratory testing services, hospitals prefer to outsource their diagnostic testing services to the large commercial laboratories and eliminate associated operational expenses required for maintaining in-house labs, thereby driving the market.
Geographic Review:
This research report analyzes major geographies and provides comprehensive analysis for North America (U.S., Canada), Europe (France, U.K., Germany, Italy, Spain, and Rest of Europe), Asia-Pacific (India, China, Japan, and RoAPAC), Latin America and the Middle East & Africa. North America region is estimated to dominate the global Influenza diagnostics market in 2020, followed by Europe, and Asia Pacific. The factors such as increasing incidence of influenza, higher adoption for technologically advanced diagnostic products, and increase in the research and development activities for influenza supported the largest share of the North America region in the influenza diagnostics market.
Key Players:
The key players operating in the global influenza diagnostics market are Thermo Fisher Scientific Inc. (U.S.), Hologic, Inc. (U.S.), Quidel Corporation (U.S.), F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Danaher Corporation (U.S.), Meridian Bioscience Inc. (U.S.),bioMérieux SA (France), Luminex Corporation (U.S.), Siemens Healthineers AG (Germany), GenMark Diagnostics, Inc. (U.S.), Sekisui Diagnostics, LLC (U.S.), altona Diagnostics GmbH (Germany), SA Scientific, Ltd. (U.S.), and ELITech Group (France), Coris Bioconcept SPRL (Belgium), and Mast Group Ltd.(U.K.), among others.
Key questions answered in the report-
• Which are the high growth market segments in terms of test type, end user, and region/countries?
• What was the historical market for influenza diagnostics across the globe?
• What are the market forecasts and estimates for the period 2019-2027?
• What are the major drivers, restraints, opportunities, and challenges in the global influenza diagnostics market?
• Who are the major players in the influenza diagnostics market?
• How is the competitive landscape and who are the market leaders in the global influenza diagnostics market?
• What are the recent developments in the global influenza diagnostics market?
• What are the different strategies adopted by the major players in the global influenza diagnostics market?
• What are the geographical trends and high growth regions/ countries?
Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research